![{ Bio Portrait }](assets/images/434_bioprofile.jpeg)
Rebecca Clegg's practice focuses on complex intellectual property litigation and counseling, particularly in the fields of medical devices, pharmaceuticals, biotechnology, and semiconductors. Rebecca regularly litigates medical device and Hatch-Waxman Paragraph IV patent infringement suits. She also has experience representing clients in commercial litigation cases.
Rebecca received her law degree from the University of Connecticut School of Law, which she attended on a full-tuition merit scholarship. While at UConn Law, she served as Competition Editor for the Connecticut Law Review, worked in the Intellectual Property and Entrepreneurship Law Clinic, and earned multiple CALI Excellence for the Future Awards. Rebecca was a summer associate with Axinn in 2014. She graduated magna cum laude from Mount Holyoke College in 2012 with a degree in History and Physics.
Professional Activities
- American Bar Association, Intellectual Property Law Section, Science & Technology Law Section, and Young Lawyers Division
- Connecticut Bar Association, Intellectual Property Section, Co-Chair
- Connecticut Bar Association, Intellectual Property Section, Legislative Liaison (2020-2024)
- Connecticut Bar Association, Young Lawyers Section
Experience
- Defended generic pharmaceutical company in a Hatch-Waxman case challenging over 460 claims from 26 patents covering Salix’s blockbuster drug Xifaxan®. Obtained judgment after a four-day bench trial that the patents directed to a method of treatment (IBS-D) and composition of matter (polymorph) were invalid as obvious.
- Defended generic pharmaceutical company in Hatch-Waxman patent litigation concerning roughly three dozen patents from seven patent families directed to controlled release or abuse deterrent dosage forms.
- Represented medical device company in patent litigation concerning veterinary surgical plates.
- Represented multinational corporation in patent litigation relating to its quantum dot television displays.
- Advised client on patent issues relating to semiconductor fabrication and manufacturing tools.
- Defended generic pharmaceutical company in Hatch-Waxman case concerning 18 patents and over 400 patent claims regarding lisdexamphetamine capsules.
- Represented developer of wireless communications modules in ITC investigation and obtained final determination of no violation on multiple grounds.
- Defended generic pharmaceutical company in Hatch-Waxman patent litigation involving a boronic acid proteasome inhibitor.
- Defended financial industry service provider from multiple indemnification claims brought by bank.
- Represented pro bono client in a civil rights suit and obtained a settlement with an economic value of more than $1 million.
Honors
- Best Lawyers “Ones to Watch” (2021– 2024)
- Lawdragon, 500 X – The Next Generation (2024)
- World Intellectual Property Review Leaders (2024)
- Super Lawyers, Rising Stars (2019 – 2023)
- Named a "2024 On the Rise – Top 40 Young Lawyers" honoree by the American Bar Association Young Lawyers Division
- Recognized as a World Intellectual Property Review Trailblazer for 2024
- Connecticut Law Tribune – “New Leader in the Law” (2022)
News
- Axinn Counsel Win New England Legal Awards
- Axinn Attorneys Appointed to the Executive Committee of the Connecticut Bar Association's Intellectual Property Section
- Axinn Attorneys Named to WIPR Leaders and WIPR Diversity's Top 100 Lists for 2024
- Axinn Attorneys Named to 2024 Lawdragon 500 X – The Next Generation
- Rebecca Clegg Named to ABA On the Rise – Top 40 Young Lawyers List
- View More ›
Thought Leadership
- How to Avoid the Section 101 Pitfall in Blockchain Patenting, IAM, August 25, 2023
- Axinn IP Update: District of Delaware Magistrate Judge Recommends Dismissal of Claims of Induced Infringement in Skinny Label Case, June 28, 2023
- Axinn IP Update: Proposed Legislation Aims at "Restoring the America Invents Act", Axinn Update, October 5, 2021
- Opinion: The Legal and Regulatory Year in Review, The Center for Biosimilars, December 24, 2020
- Old Drug, New Tricks? How the BPCIA Could Increase Generic Competition for Insulins, BioProcess Online / Biosimilar Development, June 23, 2020
- What ACA's Uncertain Future Means for Biologics Patents, Law360, February 27, 2020
- Axinn IP Update: No Collateral Estoppel after PTAB Ruling on IPR, Axinn Update, October 9, 2019
- Axinn IP Update: U.S. Supreme Court Holds That Copyright Office Must Grant Copyright Registration Before Infringement Suit Can Be Filed, Axinn Update, March 5, 2019
- The CRISPR Tug of War, IPWatchdog, August 17, 2018
Events
- ACI 11th Annual Women Leaders in Life Sciences Law Conference
- Informa Markets 13th Annual Pharma IPR Conference
- ACI 10th Annual Women Leaders in Life Sciences Law Conference
- ACI 9th Annual Women Leaders in Life Sciences Law Conference
- Sports and Entertainment Law and Antitrust and Trade Regulation
- Intellectual Property: 2020 SCOTUS Decisions and Other Landmark Cases
Education
- JD – University of Connecticut School of Law (2015)
- BA, magna cum laude – Mount Holyoke College (2012)
Admissions
- Connecticut
- U.S. Court of Appeals for the Federal Circuit
- U.S. District Court District of Connecticut